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Abstract: Antimicrobial resistance is one of the biggest threats to global health as current antibiotics
are becoming useless against resistant infectious pathogens. Consequently, new antimicrobial strate-
gies are urgently required. Drug delivery systems represent a potential solution to improve current
antibiotic properties and reverse resistance mechanisms. Among different drug delivery systems,
solid lipid nanoparticles represent a highly interesting option as they offer many advantages for
nontoxic targeted drug delivery. Several publications have demonstrated the capacity of SLNs to
significantly improve antibiotic characteristics increasing treatment efficiency. In this review article,
antibiotic-loaded solid lipid nanoparticle-related works are analyzed to summarize all information
associated with applying these new formulations to tackle the antibiotic resistance problem. The
main antimicrobial resistance mechanisms and relevant solid lipid nanoparticle characteristics are
presented to later discuss the potential of these nanoparticles to improve current antibiotic treatment
characteristics and overcome antimicrobial resistance mechanisms. Moreover, solid lipid nanoparti-
cles also offer new possibilities for other antimicrobial agents that cannot be administrated as free
drugs. The advantages and disadvantages of these new formulations are also discussed in this review.
Finally, given the progress of the studies carried out to date, future directions are discussed.
Keywords: antibiotics; antimicrobial resistance; multidrug-resistant bacteria; drug delivery systems;
solid lipid nanoparticles
1. Introduction
The discovery and therapeutic application of antibiotics have enabled the develop-
ment of modern medicine. However, the abuse and misuse of antibiotics in medicine,
animal health, and agriculture over the years have led to the emergence of multidrug-
resistant (MDR) bacteria and the loss of efficacy of existing antibiotics. Antibiotics are
broadly employed to treat infectious diseases. However, this intensive application also has
developed some associated problems. According to World Health Organization (WHO),
antimicrobial resistance (AMR) is one of the biggest threats to global health, and the world
urgently needs to develop new tools and strategies to minimize this problem [1,2]. It has
been estimated that this situation would lead to a scenario where infections caused by
MDR bacteria could cause 10 million deaths each year by 2050. Moreover, this damage
would also impact the economy, leading to a catastrophic situation whereby 2030 AMR
could force up to 24 million people into extreme poverty [3].
The European Centre for Disease Prevention and Control (ECDC) has published
some guidance on preventing and controlling infectious diseases and developing different
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strategies and action plans on AMR [4]. In these action plans, the need for new antimicrobial
strategies is urgently required. Nonetheless, in the last years, pharmaceutical companies
have reduced the investment and efforts to discover new antimicrobial drugs due to the
financial risks that developing a new drug implies [5]. This situation urges us to find new
properties for existing antibiotics to alleviate the AMR problem as we search for other
novel antimicrobial strategies.
In this regard, nanoscience and nanotechnology could be a realistic solution to the
AMR problem, as the development and study of drug delivery systems (DDSs) have
provided new possibilities to improve the effectiveness of different therapeutic drugs for
other complex diseases like cancer, autoimmune diseases or pathologies in the central
nervous system [6–8]. Among all the developed DDSs, solid lipid nanoparticles (SLNs) are
of particular interest not only due to their low toxicity but also because their production at
a large scale is technically and economically feasible.
Hence, this review is focused on applying antibiotic-loaded SLNs as a promising
strategy to overcome or, at least, reduce AMR. First, basic knowledge about AMR mecha-
nisms is presented. Next, the most relevant SLNs characteristics are described so that the
advantages of using antibiotic-loaded SLNs against AMR mechanisms can be examined.
Then, the main processes by which antibiotic-loaded SLNs can be used to reduce AMR
mechanisms have been explained based on currently published data. Furthermore, com-
bined therapy of different antibiotics or delivery of new antimicrobials is presented. Finally,
future perspectives and conclusions are discussed. For developing this review, PubMed
and Web of Science databases have been analyzed, searching for papers related to antibiotic
resistance in bacteria and SLNs without limiting the publication data of the papers.
2. Antimicrobial Resistance Mechanisms
Antimicrobial resistance mechanisms are naturally occurring processes that existed
much earlier than the discovery of the first antibiotic as a drug for therapeutic purposes [9].
In fact, antibiotics play different roles in bacterial communities beyond killing competing
bacteria to conquer new ecological niches. These functions include signaling and com-
munication between the different members of the bacterial community [10]. Given the
importance of these functions for the survival of bacteria, it has now been demonstrated
that the production of antibiotics is very ancient (from 2 Gyr to 40 Myr ago) and conse-
quently, antibiotic–resistance mechanisms have evolved in parallel [9]. Nonetheless, the
intensive use and misuse of antimicrobial agents has accelerated the emergence of more
antimicrobial-resistant bacteria or even MDR bacteria.
From a genetic point of view, antibiotic–resistance mechanisms are divided into
intrinsic and extrinsic mechanisms. Both provide bacteria advantageous phenotypes to
survive in hostile environments [11].
Intrinsic resistance mechanisms are inherent structural or functional characteristics
universally found within the genome of a bacterial species. They are independent of
antibiotic selective pressure and not related to the movement of genetic material between
different organisms. Some of the intrinsic antibiotic resistance mechanisms are reduced
membrane permeability, overexpression of efflux pumps, expression of antibiotic modify-
ing enzymes, modified antibiotic-targets, or biofilm-formation capacity [11].
Extrinsic resistance mechanisms consist of all acquired or developed traits that confer
resistance to antibiotics. These beneficial features can be achieved by three main processes:
(i) mutations that alter the DNA sequence; (ii) genetic rearrangements; and (iii) acquisition
of new genetic material from other bacteria via a process known as horizontal gene transfer
(HGT). Nowadays, it is well-known that a high proportion of the bacterial genome corre-
sponds to horizontally acquired genetic material [4]. In particular, genes encoding modified
antibiotic targets, antibiotic transporters, regulators that control antibiotic transporters and
those encoding antibiotic-modifying enzymes can be shared between bacteria to obtain an
advantageous characteristic to survive to environmental specific pressure.
Nanomaterials 2021, 11, 1251 3 of 27
Bacterial conjugation is one of the main mechanisms by which bacteria can acquire
antibiotic resistance genes through HGT [12]. Although these mechanisms are naturally
occurring, the abuse of antibiotics has exercised an additional and continuous pressure
that has increased horizontal gene transfer among bacteria, enhancing MDR bacteria
selection [13].
In general, the main strategies related to antimicrobial resistance mechanisms are
reduction of the intracellular drug concentration thanks to a (i) decreased cell wall per-
meability, or an (ii) increased expression of efflux pumps; (iii) expression of antimicrobial-
modifying enzymes that deactivate antibiotic molecules and (iv) modification of the antibi-
otic target [11]; or community-related drug resistance mechanisms, such as (v) intracellular
infection [14] and (vi) biofilm-formation [15]. Antibiotic resistance mechanisms mentioned
in this section are summarized in Figure 1.
Figure 1. Schematic representation of the intracellular (left) or community (right) antibiotic resistance mechanisms.
Intracellular antibiotic resistance mechanisms are (A) decreased cell wall permeability, (B) increased expression of efflux
pumps, (C) expression of antimicrobial-modifying enzymes that deactivate antibiotic molecules and (D) modification of the
antibiotic target. Community antibiotic resistance mechanisms are (E) intracellular infection or (F) biofilm-formation.
2.1. Reduced Drug Permeability
The bacterial cell wall has a complex architecture that regulates molecular permeation
to preserve cellular functions and bacterial characteristics. As a consequence, cell walls
can considerably reduce the access of antibiotics to bacteria. This is especially true for
anionic antibiotics, as the cell wall comprises many anionic molecules, and electrostatic
repulsion impedes antibiotic penetration. Antibiotic characteristics are of particular impor-
tance when acting against Gram-positive or Gram-negative bacteria due to their different
wall architecture. Gram-positive bacteria present a cytoplasmic membrane covered by a
hydrophilic peptidoglycan network. Gram-negative bacteria have a more complex archi-
tecture in which the cytoplasmic membrane is surrounded by a thin peptidoglycan layer
that is covered by an asymmetric outer membrane composed of phospholipids in its inner
leaflet and lipopolysaccharides in the outer leaflet. The cytoplasmic membrane and the
outer membrane are separated by the periplasm.
This complex structure reduces molecule trafficking dramatically. Thus, Gram-negative
bacteria express some transport proteins and channels (i.e., porins) to allow the perme-
ation of the hydrophilic molecules necessary to survive. Some antimicrobials (generally
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small hydrophilic ones) can penetrate bacterial cell walls taking advantage of transport
proteins and porins. Consequently, bacteria have developed the capability to modify the
structure or directly reduce the expression of these proteins to diminish antibiotic perme-
ability [16]. Therefore, resistance mechanisms based on reduced permeability are especially
effective in Gram-negative bacteria, decreasing dramatically therapeutic options to treat
infections [16–18]. However, this mechanism can also be found in Gram-positive bacteria,
such as vancomycin-resistant Staphylococcus aureus [19].
2.2. Overexpression of Efflux Pumps
As mentioned before, bacteria present transport proteins and some of them are efflux
pumps that expel some solutes out of the cell, allowing the active regulation of their internal
environment and the extrusion of toxic molecules, such as antibiotics. Efflux pumps are
widespread in different organisms, and active efflux of many antibacterial agents has been
well documented in many Gram-positive and Gram-negative bacteria [17]. Five different
transport proteins have been identified: (i) the ATP-binding cassette (ABC) superfamily;
(ii) the major facilitator superfamily (MFS); (iii) the multidrug and toxic compound ex-
trusion (MATE) family; (iv) the small multidrug resistance (SMR) family (a subgroup of
the drug/metabolite transporter superfamily); and (v) the resistance-nodulation-division
(RND) superfamily. For Gram-negative bacteria, proteins belonging to the RND family are
the most relevant ones, while for Gram-positive bacteria, drug efflux pumps are usually
non-RND [20]. Apart from reducing the intracellular concentration of toxic molecules,
efflux pumps have other important physiological functions, such as bacterial colonization,
quorum-sensing control, virulence regulation, biofilm formation and other fitness responses.
Therefore, regulation of efflux pump expression and activity is a complex process with
several factors and mechanisms influencing such regulation. In particular, antibiotics can
induce efflux pump expression, paradoxically contributing to the resistance capacity of the
bacteria. Therefore, combining antibacterial drugs with efflux pump inhibitors has been
proposed as an alternative strategy to overcome antibiotic resistance [20].
2.3. Antibiotic-Modifying Enzymes
Some bacterial strains express enzymes able to modify or destroy host tissues and
deactivate antibiotics. Genes encoding these enzymes can be intrinsically part of the
bacterial genome or can be acquired by HGT. Thus, bacteria expressing an antibiotic
destructing enzyme acquire a weapon against the antibiotic and develop resistance. This
resistance mechanism can be acquired by Gram-positive or Gram-negative bacteria [21].
One of the most known examples of antibiotic-modifying enzymes is β-lactamases [22].
These enzymes can hydrolyze and deactivate β-lactam drugs, the most widely used group
of antimicrobial agents. The expression of β-lactamases is the most common resistance
mechanism in Gram-negative bacteria, and the genes encoding these enzymes can be
intrinsically part of the genome or acquired [23,24].
2.4. Modification of the Drug Target
Some antibiotics target bacterial proteins and can modulate their functions, generally
forcing loss or inhibition of bacterial proteins and, therefore, bacterial functions. The
interaction affinity between the antibiotic and its target defines the efficiency and the
efficacy of the antimicrobial treatment. Additionally, the specificity of antibiotic–protein
interaction delimits the selectivity of the antibiotic. As a consequence, an antibiotic can have
an effect on a wide spectrum of bacteria or can be more restrictive to a specific strain. To
overcome antibiotic effects, bacteria can produce structural changes in target proteins that
modify the antibiotic–protein interaction, triggering a reduction of the efficiency and/or
efficacy of the drug. One of the most studied examples of drug target modification is
structural changes in ribosomal subunits that lead to a partial or complete reduction of
the antibiotic binding. Ribosomes are important antibiotic targets, as their structure is
different from eukaryotic ribosomes, thus, allowing selective toxicity of antibiotics against
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prokaryotic cells. Unhopefully, bacteria have developed many different mechanisms that
modify ribosomal structures and protect themselves against antibiotic effects [25]. One of
those strategies is the methylation of the ribosome in the target site so that the antibiotic
cannot exert its activity, and this mechanism can be observed in both Gram-positive or
Gram-negative bacteria [21].
2.5. Intracellular Infection
Some clinically relevant bacteria, such as Mycobacterium tuberculosis, Salmonella enterica,
Chlamydia trachomatis and Listeria monocytogenes, called intracellular pathogens, can invade
host cells, multiply inside them and modulate host cell biology [14]. This mechanism
provides protection against antibiotics and against the host immune system. As a con-
sequence, these pathogenic bacteria (Gram-positive or Gram-negative) can disseminate
and infect different tissues in the body [14]. When bacteria invade eukaryotic cells, a new
challenge is added to the previously mentioned difficulties in drug distribution, as the
plasma membrane is an impermeable barrier to small and polar drugs. Therefore, intracel-
lular infections are difficult to eradicate because bacteria are protected against antibiotic
drugs, as optimal intracellular drug concentration is difficult to obtain. Thus, the ability to
infect host cells is another AMR mechanism that should be addressed by developing new
therapeutic strategies, such as developing DDSs for antibiotic administration [14].
2.6. Biofilm Formation
Biofilms are microbial communities surrounded by extracellular polymeric molecules
attached to inert or living surfaces [26]. For developing a biofilm, planktonic bacteria
transform into adherent bacteria due to a differential protein expression and extracellular
matrix formation. Thus, bacteria present in biofilms exhibit different phenotypes compared
to planktonic ones.
Biofilm-forming bacteria (both Gram-positive and Gram-negative) develop antibiotic
resistance; owing to this inherent resistance, the treatment of biofilm-associated infections
is considered a challenging task. Several mechanisms have been reported as responsible
for the antimicrobial resistance in biofilm structures, such as poor diffusion of antibiotics
through the biofilm matrix, physiological changes due to slow growth rate and starvation
responses, phenotypic change of the cells forming the biofilm, quorum-sensing, overex-
pression of efflux pumps, and the presence of particularly resistant cells that avoid death
when exposed to antimicrobials [27].
3. New Strategies to Overcome Antimicrobial Resistance Mechanisms
As mentioned before, the number of newly discovered antimicrobial drugs has been
reduced in the last years. This situation, in combination with the increase in MDR bacteria,
leads to an emergency situation where we are running out of effective antibiotics. Moreover,
the appearance of resistant bacteria against these new drugs seems highly probable.
In this context, it has been suggested that developing new strategies to overcome
bacterial resistance mechanisms is needed. Aiming to provide solutions to this problem,
nanotechnology has expanded the therapeutic options of current antibiotic drugs through
the design of DDSs, able to improve antibiotic characteristics, reduce AMR mechanisms
and/or facilitate drug administration.
Therefore, a proper nanocarrier would avoid or reduce AMR mechanisms by increas-
ing antibiotic effectiveness. Typically, DDSs can increase drug efficiency by (i) enhancing
drug stability or solubility; (ii) improving release kinetics; (iii) performing a targeted drug
delivery to a specific cell, tissue or molecule; (iv) allowing a higher drug penetration; or
(v) obtaining better biodistribution. Moreover, it has been observed that nanocarriers
can enhance drug accumulation near infections because blood vessels at infection sites
are leaky [28]. Improving such relevant pharmacokinetics and pharmacodynamics fac-
tors can contribute to the reposition of antibiotics that nowadays are ineffective against
resistant bacteria.
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There is a wide repertoire of nanoparticulated options to treat each therapeutic prob-
lem by a tailored approach. Among the most studied organic DDSs, it is worth mentioning
micelles, dendrimers, polymeric nanoparticles or micelles, polymer–drug/protein conju-
gates, and lipid nanoparticles. Several inorganic nanoparticles have also been employed for
drug delivery applications, such as quantum dots, metallic nanoparticles or mesoporous
silica nanoparticles [29].
Lipids are particularly promising components for DDSs since they are biocompatible
molecules, able to self-assemble and mimic the structure and function of cellular struc-
tures [30]. Therefore, lipid-based nanoparticles are less toxic and more biocompatible
than inorganic or polymeric nanoparticles [31]. Different nanoparticles can be obtained
composed of biocompatible and biodegradable lipids: liposomes, nanostructured lipid
carriers or solid lipid nanoparticles, for instance. Liposomes have been the most applied
lipid-based drug delivery systems, and they have also been approved for clinical treat-
ments [32]. Nonetheless, they present a low capacity to encapsulate hydrophobic molecules,
low storage stability and eventual drug leakage in the media [31,32].
Solid lipid nanoparticles (SLNs) offer an interesting alternative to liposomes as promis-
ing robust nanocarriers for controlled drug delivery. They present a hydrophobic internal
core composed of solid lipids at room or body temperature and an external stabilizing
layer formed by amphiphilic surfactants and sometimes co-surfactants (Figure 2).
Figure 2. Scheme of the proposed structure of a solid lipid nanoparticle showing the solid lipid
matrix, the surfactant, and the co-surfactant.
They present many advantages, such as low toxicity, high stability, high biocompati-
bility and biodegradability, and the remarkable capacity to incorporate both hydrophilic
and lipophilic compounds. In addition, they enable a controlled release of the incorporated
drug, and they provide chemical protection to the compound. They can be produced by
simple and economical large-scale production, and it has been demonstrated that they can
be effectively administrated through a wide variety of routes (oral, parenteral, rectal, nasal,
ocular, etc.) [31]. The components, production methods and characterization protocols
for the SLNs development are beyond the scope of this review and are already reviewed
elsewhere [31,33–35].
Another advantage of SLNs is that their surface can be easily modified to modulate
some relevant biological interactions. For instance, signaling molecules can be added to
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obtain targeted drug delivery, or surface characteristics can be altered by adding polymers
(such as polyethylene glycol, PEG) to obtain a steal drug delivery system inside the
organism [31,36]. The addition of hydrophilic molecules to the SLNs surface can also
modulate the formation of the “protein corona”, i.e., the addition of plasma proteins to
SLNs surface when they enter the bloodstream [37]. This protein corona formation occurs in
different lipid nanoparticles (including SLNs [38]), and it has been demonstrated that it can
alter nanoparticle biodistribution [37,39]. It has been demonstrated that the incorporation
of PEG molecules led to a significantly reduced amount of bound proteins [40]. Thus
surface modification can be a relevant advantage for systemic SLNs administration.
In summary, compared to other DDSs systems, SLNs are less toxic and more bio-
compatible than nanoparticles that are not composed of lipids. Moreover, they present
a versatile and stable alternative to liposomes, as they present good loading capacity for
both hydrophobic and hydrophilic drugs. These characteristics make SLNs suitable DDSs
for antibiotic drug delivery systems, as they present good permeation through biological
barriers, good cell uptake, and they can be administrated through different routes [31,32]
4. Relevant SLNs Characteristics for an Efficient Drug Delivery
It has been described that some SLNs characteristics influence drug stability, release
kinetics, selective drug delivery or the ability of drugs to penetrate the bacteria and infected
host cells, thereby increasing their efficiency. Moreover, SLN characteristics define their be-
havior in a biological environment. Unfortunately, it is not easy to determine the correlation
between SLNs characteristics and the way they act in vivo. Thus, it is difficult to predict or
extrapolate the ability of a new formulation. Therefore, a detailed characterization process
is always required in each project. Nonetheless, some research has been performed to shed
some light on the characteristics that SLNs need to improve antibiotic efficiency and reduce
resistance mechanisms, as it is discussed in the next subsections. For SLNs formulations,
the characterization of each new preparation requires at least the determination of (i) size,
polydispersity and zeta-potential; (ii) solid-state and crystalline structure of the lipid core;
and (iii) drug entrapment efficiency and loading capacity.
4.1. Size, Polydispersity and Zeta-Potential
Although different physicochemical characteristics can be evaluated, size, polydisper-
sity and surface charge are the most relevant characteristics as they can define cell uptake,
biodistribution or toxicity in vivo [32].
Nanoparticle size generally states for the mean diameter of a nanoparticle population.
As it is usually determined by dynamic light scattering, nanoparticle size refers to the mean
hydrodynamic diameter of the nanoparticle population. Nonetheless, these values should
be confirmed by other techniques, such as electron microscopy or atomic force microscopy.
Polydispersity or polydispersity index (pdi) is a parameter that defines the size range
of a nanoparticle suspension; therefore, it defines the uniformity of the size distribution of a
nanoparticle population. The theoretical range of the index is 0–1, and bigger nanoparticle
size-uniformity correlates to smaller polydispersity index values. To develop predictable,
safe and stable DDSs, it is important to obtain homogeneous nanoparticle suspensions.
Thus, small pdi values are desirable. For SLNs suspensions, pdi values of 0.3 or below are
considered acceptable, indicating a homogeneous population [34,41].
Zeta-potential reflects the potential difference between the electrophoretically mobile
particles and the layer of dispersant around them. It is mainly used to describe nanoparticle
stability, as higher zeta-potential values refer to bigger electrostatic repulsion, and this is
supposed to avoid particle aggregation and stabilize the nanoparticle suspension [42]. Thus,
nanoparticles with a zeta-potential >±30 mV are considered highly stable. Nonetheless, as
other interactions apart from electrostatic forces can influence particle stability (i.e., van
der Waals attractive forces), it is possible to obtain stable particles with low zeta-potential
values and vice versa. Zeta-potential may also be applied to assess the surface charge of
nanoparticles, provided certain conditions are respected in the measuring protocol [34,42].
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SLNs have been described as nanoparticles with a mean diameter range of 50–1000 nm.
Different size ranges (from 85 nm to 615 nm) have been obtained with different SLNs for-
mulations that significantly enhance the antibiotic activity of different drugs in planktonic
or biofilm-forming bacteria (Tables 1 and 2). Nonetheless, depending on the purpose of
the designed SLNs, a more specific size range may be required. For instance, in systemic
administration, it seems that 50–200 nm-sized nanoparticles are optimal to obtain a long
circulatory condition, but this range can vary depending on nanoparticle composition
and shape [41,43,44]. Moreover, SLNs larger than 500 nm present reduced access to de
lymphatic system [45] and nanoparticle size also seems relevant to treat central nervous
system infections, as only SLNs smaller than 200 nm seem to efficiently overpass the
blood–brain barrier [41,44]. Additionally, to treat intracellular infections, it must be taken
in mind that nanoparticle size can influence nanoparticle uptake mechanism by infected
eukaryotic cells, and the internalization pathway can be relevant for the improvement of
drug efficiency [46,47].
The nature of the cell wall can determine the interactions between SLNs and bacteria.
Therefore, each SLNs composition can interact by a different pattern with different bacterial
strains. In this regard, it is important to take in mind that highly efficient SLNs must
interact with the cell wall to deliver the cargo into the cell. As both Gram-negative and
Gram-positive bacteria are negatively charged, it has been suggested that efficient DDSs
should have a positive charge to facilitate electrostatic interactions [48–50]. Pignatello and
coworkers have reported that positive charged SLNs allowed a better interaction with
the bacteria surface and an enhanced penetration through their cell wall, as the growth
inhibitory activity tended to enlarge with the increasing SLNs positive charge. Among
all the bacterial strains they tested, this feature was more evident against Gram-negative
bacteria [49]. In a recent paper, González-Paredes and coworkers analyzed the interactions
between different SLNs suspensions and bacterial walls using confocal microscopy and flow
cytometry. They observed that cationic SLNs, but not anionic SLNs, displayed rapid and
extensive interaction with bacterial cells, independent of their lipid core composition [50].
Interestingly, they also observed that the lipid core seemed to have an important role
in determining the intracellular delivery of their cargo (an oligonucleotide), obtaining
the most efficient intracellular delivery with tripalmitin-based lipid core. Nevertheless,
other researchers demonstrated that the incorporation of antibiotics into anionic SLNs also
improved drug efficiency [51–53].
Fazly Bazzaz and coworkers prepared and characterized different anionic SLNs com-
positions carrying Eugenia caryophyllata essential oil, a well-known antibacterial and an-
tifungal substance. They observed that incorporation of the essential oil in SLNs effec-
tively reduced the concentration required for growth inhibition and killing of microorgan-
isms [54]. Interestingly, the formulations were less effective against Gram-positive bacteria
than against Gram-negative bacteria and fungi. These differences highlight the relevance
of different SLNs parameters (size, composition, morphology) on nanoparticle-microbe
interactions [18].
Additionally, when the final goal is to treat an intracellular infection, the eukaryotic
cell uptake of SLNs plays a key role in obtaining high intracellular drug concentrations
and ensure treatment efficiency. It has been described that negatively charged SLNs are
taken more efficiently by macrophages [55], are less toxic and present better antibiotic
effects. Other interesting published results highlighted that SLNs size could affect more
deeply than a charge to the cell uptake of the encapsulated drug in macrophages. In a
noteworthy work, Xie and coworkers obtained enrofloxacin-loaded SLNs and analyzed
cell uptake of the drug in a macrophage cell line (RAW 264.7). First, they analyzed
SLNs suspensions with different sizes (i.e., 150–605 nm diameter), maintaining negative
zeta-potentials from −3.1 to −24.9 mV. All SLNs suspensions improved intracellular
drug concentration comparing to free drug incorporation, but they also observed that the
intracellular concentration of the antibiotic was 1.147 µg/mg of protein for the biggest
size SLNs suspension (605 nm) and 0.336 µg/mg of protein for the smallest one (150 nm).
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Next, they also prepared SLNs suspensions with different zeta-potentials adding different
percentages of dimethyldioctadecyl ammonium chloride. They observed that the net charge
and not its positivity or negativity influenced drug uptake efficiency. Finally, comparing
SLNs suspensions with different characteristics, they concluded that particle size played
a more important role than zeta potential for the intracellular delivery of the drug in
macrophages [56].
Therefore, in view of these results, it is relevant to holistically consider the final
purpose of tailored antibiotic-loaded SLNs, not only from the point of view of the infectious
agent but also considering the location of the infection and the treatment attending to the
condition of the patient.
4.2. Solid State and Crystalline Structure of the Lipid Core
As mentioned before, SLNs consist of a lipid core that presents a solid state at room
or body temperature. This characteristic is relevant to achieve a controlled drug release,
as the mobility of the drug in a solid lipid matrix is substantially lower than in oil [33,35].
More importantly, the quality of an SLN formulation depends on the crystal structure of
the lipid matrix, as the solid state of the lipids influences particle stability and controlled
drug release. For a DDS, stability and controlled drug release are central characteristics, as
the main function of a nanocarrier is to improve drug stability and release kinetics.
The crystal structure of an SLNs formulation cannot be presumed because it depends
on multiple factors, such as composition or production method, among others. In fact,
supercooled melts (i.e., lipid structures that do not crystallize although being below their
melting point) can appear, meaning that crystallization does not take place during the
production process. Eventually, supercooled melts tend to crystallize in an uncontrolled
manner leading to large crystal formations and particle aggregation [31]. Therefore, the
solid state of the lipid matrix must be carefully determined, usually by infrared spec-
troscopy or differential scanning calorimetry.
In addition, depending on SLNs formulation during the SLNs formation process,
lipids can form different crystal species with different stabilities. Therefore, after a period
(usually during SLNs storage time), recrystallization processes can occur, leading to more
stable structures [31,33]. Those possible polymorphic transitions are one of the main
drawbacks of SLNs formulations, as, during the recrystallization process, physicochemical
characteristics of SLNs formulations can change, and expulsion of drug molecules can
occur. Consequently, apart from determining the state of the lipid matrix, SLNs stability
studies must be performed to discard changes in SLNs characteristics during the storage,
thus, ensuring pharmaceutical standards.
Given the potential complications related to the lipid crystallization process, another
approach was proposed by different research groups. Liquid lipids were added to the
formulations, partially replacing the solid lipid component, and nanostructured lipid
carriers (NLCs) were obtained (Figure 3).
These DDSs are considered as “second-generation” SLNs (as they were presented few
years after SLNs) because they do not present recrystallization processes. Thus, they avoid
one of the main SLNs drawbacks [31,34,57].
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Figure 3. Schematic representation of lipid core structure of SLNs (left) and NLCs (right). Geometrical forms in the NLCs
scheme represent different solid lipid crystals.
4.3. Entrapment Efficiency and Loading Capacity of the Drug
Entrapment efficiency (EE) is defined as the percentage of drug that has been in-
corporated into the nanoparticle suspension compared to the total drug content in the
initial formulation. Loading capacity (LC) is related to the amount of total entrapped drug
divided by the total nanoparticle weight. This magnitude indicates the amount of drug
delivered per amount of nanocarrier.
Both characteristics depend on the solubility of the drug in the lipid matrix, as good
compatibility between the drug chemical structure and the lipid matrix ensures a good
partition of the drug between the lipid and the surrounding aqueous solution. Therefore,
the type and concentrations of lipids and surfactants are the most important factors that
can influence drug incorporation [58].
In most of the published works, the encapsulation efficiency of different SLNs for-
mulations is above 70% [34]. Nonetheless, it has been published that SLNs present a low
loading capacity comparing to other DDSs and that this drawback could also be improved
by adding liquid lipids to the lipid matrix. Thus, according to the literature, apart from
presenting better storage stability, NLCs presents better drug loading capacity [31,34,57].
However, it is worth mentioning that despite being presented as a second-generation SLNs
only seven years after the first publication relative to SLNs, the SLNs cover approximately
70% of the investigations carried out with lipid nanoparticles until December 2018 [34].
Thus, NLCs still needs scientific validation, and SLNs continue to be promising DDSs and
remain the first choice in developing drug delivery projects. In any case, whether with the
most studied SLNss at present or in the future with the NLCs, the most important aspect is
to have a thorough knowledge of the potential drawbacks and limitations of these DDSs to
compensate them by enhancing their advantages and adapting each DDSs to the needs of
each particular project.
5. Solid Lipid Nanoparticle to Improve Drug Delivery
It has been broadly demonstrated that a proper DDS improves drug delivery, enhanc-
ing treatment efficiency [6–8]. For antimicrobial drugs, several formulations have been
developed and tested to improve the antimicrobial drug effect and help to revert drug
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resistance processes. As mentioned before, SLNs can improve drug stability, solubility or
release kinetics, but, more interestingly, to reduce AMR, they improve drug permeability
and selective delivery of incorporated antibiotics.
5.1. Improved Permeation and Bioavailability
Some formulations can enhance antibiotic efficiency by improving bioavailability,
thus, allowing oral [59–66], intramuscular [67], pulmonary [68,69], skin [70–72] or sub-
cutaneous [73,74] drug administration. Other groups have demonstrated that SLNs can
increase antibiotic activity by facilitating drug permeation through different barriers in
the eye [75–80], through the mucosal barrier [81,82], or even through the blood–brain
barrier [83].
5.2. Improved Selectivity
A relevant strategy to improve efficiency and reduce antibiotic resistance when ad-
ministering antibiotics into an organism is developing selective drug delivery systems that
target bacteria. A site-directed release of antibiotics enhances drug concentration in the
infection site and reduces unspecific side effects (i.e., possible systemic toxicity), which
also enables applying higher drug concentrations and reduces bacterial resistance. In this
regard, some interesting works demonstrated that drug targeting by modulation of SLNs
surface with selective molecules, such as antibodies, also increased loaded drug efficiency
or reduced cytotoxic side effects of biocides that do not develop resistance [84]. In this
context, incorporating cytotoxic biocides into SLNs can reduce cytotoxicity in eukaryotic
cells while improving antimicrobial properties [85]. For instance, it has been demonstrated
that incorporation of tilmicosin in castor oil-SLNs can reduce drug side effects, such as
cardiotoxicity [86].
Another described strategy to obtain selective drug delivery is to develop pH-sensitive
SLNs, which can tune their release kinetics depending on the pH of the environment. The
aim of these formulations is to retain antibiotic drugs into the SLNs until the nanocarrier
reaches the infection site where the pH is lower and, thus, the antibiotic is efficiently
released in the target tissue [87,88].
6. Solid Lipid Nanoparticles Can Reduce Antibiotic Resistance Mechanisms
As is going to be discussed in this section, several works have been published demon-
strating the potential of SLNs to reduce AMR mechanisms and, thus, the multiple ad-
vantages of applying this type of DDSs to obtain an optimized formulation for in-use
antibiotics. As mentioned in the previous section, the new formulations can increase the
efficiency of current antimicrobial treatments by improving drug permeation, not only
through different barriers in the organism but also through the bacterial cell wall. Moreover,
it has been demonstrated that SLNs can (i) reduce efflux pump-mediated drug expulsion,
(ii) avoid the effect of antibiotic-modifying enzymes (Figure 4), (iii) improve cell uptake to
treat intracellular infections or (iv) reduce biofilm formation or viability of biofilm-forming
bacteria (Figure 5).
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Figure 4. Schematic representation of the main antibiotic resistance mechanisms and the effect of antibiotic encapsulation into
SLNs to avoid/reduce AMR mechanisms. Main antibiotic resistance mechanisms are (A) decreased cell wall permeability,
(B) overexpression of efflux pumps and (C) antibiotic-modifying enzymes. The boxes depict ways to circumvent resistance
mechanisms by incorporating antibiotics in SLNs. SLNs can (A) improve drug permeability, (B) reduce the activity of efflux
pumps or (C) protect antibiotics from drug modifying enzymes.
Figure 5. Schematic representation of community antibiotic resistance strategies and the effect of antibiotic incorporation
into SLNs to avoid them. (A) Intracellular infection and (B) biofilm formation. In both cases, how can antibiotic-loaded
SLNs overcome these strategies is represented. SLNs can improve eukaryotic cell uptake to treat intracellular infections.
SLNs can reduce biofilm formation or viability of biofilm-forming bacteria.
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6.1. Drug Efflux Pumps
One of the main strategies of antibiotic resistance is to reduce intracellular drug
concentration (Figure 4). In this regard, some cells overexpress drug efflux pumps encoding
genes to increase drug expulsion capacity, helping bacteria to develop resistance. According
to the literature, different nanoparticle formulations can inhibit the transporter activity
effectively [89].
Although many works demonstrate that SLNs enhance intracellular drug concentra-
tion [50,90], to our knowledge, only two works, in yeasts [91] and mycobacteria [92], have
related the ability of SLNs to provide an effective treatment to the reduction of the drug
efflux activity. Nevertheless, these authors describe the increased intracellular concentra-
tion of the antibiotic and its antimicrobial effect. Unfortunately, they have not been able to
determine whether this effect is due to reduced pump activity or other reasons. This lack
of mechanistic information hinders the potential optimization of DDSs. Therefore, more
mechanistic information about how SLNs escape drug-efflux pumps are needed to find the
best characteristics by which SLNs would increase drug effectiveness.
6.2. Enzymatic Degradation
As mentioned in Section 2.4, bacteria can express antibiotic modifying enzymes to
inactivate antibiotics and acquire resistance. Nanocarriers can reduce this inactivation by
protecting antibiotics from enzymatic activity, thus, avoiding this resistance mechanism
(Figure 4) [28].
Although several publications demonstrate the capability of different organic nanopar-
ticles to protect antibiotics from bacterial enzyme degradation (e.g., polymeric nanoparti-
cles [93], liposomes [94] and micelle–lipid nanocapsules [93–95]), there is no publication,
at least in our knowledge, related to the protection against enzymatic activity presented
by SLNs.
Nonetheless, some works demonstrate the ability of SLNs to protect incorporated
peptides from hydrolytic enzyme activities [96], but data supporting the opposite idea
can also be found in the literature [97]. Therefore, the potential of SLNs to protect drugs
from enzymatic degradation should be further analyzed, and more experimental results
are required.
6.3. Infections by Intracellular Pathogens
As previously described, infections caused by intracellular pathogens are particularly
difficult to treat. In this regard, SLNs are capable of interacting with lipid membranes,
delivering incorporated drugs to eukaryotic cells by active or passive cell uptake mech-
anisms [98]. Therefore, loading antibiotics into SLNs can increase the permeation of the
drug in the eukaryotic host cell, increasing antibiotic drug concentration and improving
antibiotic efficiency (Figure 5).
Different works demonstrating the ability of antibiotic-loaded SLNs to increase bacte-
ria death inside macrophages have been published [55,56,99,100]. Hosseini and coworkers
obtained doxycycline-encapsulated SLNs composed of palm oil, lecithin and Tween-80
to improve drug efficiency against Brucella melitensis, an infection that to date has no effi-
cient treatment because the survival of the bacteria inside the macrophages makes them
safe from the immune system and disrupts drug delivery mechanism. They observed
that doxycycline-loaded SLNs were significantly more effective in reducing the number
of bacteria inside macrophages than free doxycycline [99]. Even more, this formulation
also improved the antibacterial capacity of doxycycline to treat chronic brucellosis and
preventing its relapse in vivo [101].
The ability of SLNs to interact with eukaryotic cells has a direct impact on the capabil-
ity of SLNs for intracellular delivery of antibiotics. In a previously mentioned work, Xie and
coworkers developed docosanoic acid-based SLNs with different properties loaded with
enrofloxacin and analyzed their cellular uptake, intracellular elimination of the drug and
antibacterial activity against intracellular Salmonella CVCC541 in RAW 264.7 macrophages.
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They observed that all SLNs formulations enhanced the cellular uptake of the drug and that
this enhancement was significantly influenced by the size rather than by the charge (cationic
or anionic). Besides, after removing the extracellular drug, eliminating SLNs-encapsulated
enrofloxacin from the cells was significantly slower compared to free enrofloxacin, pro-
longing optimal intracellular drug concentration. More importantly, the inhibition effect
against intracellular Salmonella CVCC541 of enrofloxacin-loaded SLNs was stronger than
a free drug after all the incubation periods [56]. In a latter work, they analyzed the effect
of using different saturated fatty acids as lipid matrix, developing SLNs composed of
docosanoic acid (C22), octadecanoic acid (C18), hexadecanoic acid (C16), and tetradecanoic
acid (C14). They observed that entrapment efficiency, loading and particle size, increased
with increasing the fatty acid chain length, obtaining the best results with docosanoic acid.
Specifically, all formulations presented similar cytotoxicity, but docosanoic acid-composed
SLNs presented the best cellular uptake of enrofloxacin, longer intracellular retention of
the drug and stronger antimicrobial efficacy against intracellular Salmonella CVCC541.
More interestingly, they observed that fatty acid chain length influences the intracellular
distribution of the drug. SLNs with longer fatty acids tend to accumulate in the perinucleus
of RAW 264.7 cells, while shorter ones are mostly absorbed in the cell membrane. The
authors associate these results to the higher lipophilicity of long-chain fatty acids, more
than to the differences in the SLNs sizes, indicating that lipid matrix lipophilicity could be
another relevant factor to take in mind to design SLNs for intracellular infections [90].
An interesting strategy to improve intracellular drug concentration is the modification
of the SLNs surface to stimulate active cell uptake. In recent years, mannose has attracted
some attention to treat intracellular lung infections because alveolar macrophages over-
express mannose receptors to recognize mannan-coated cell walls in organisms, such as
Mycobacterium tuberculosis, Streptococcus pneumonia, Yersinia pestis, Candida albicans, Pneu-
mocystis carinii, Cryptococcus neoformans, and Leishmania [102]. For this reason, mannose-
receptors are interesting targets to stimulate cell uptake of antibiotic-loaded SLNs in
alveolar macrophages to increase antibiotic concentration inside cells. Different groups
have developed SLNs formulations modifying nanoparticle surfaces with mannose to
take advantage of this mechanism [55,100]. In recent work, Ma and coworkers modified
SLNs surface with mannose to activate macrophage uptake by mannose receptors, and this
specific endocytic pathway improved nanoparticle cell uptake. Additionally, to improve
drug retention and efficiency, the antibiotic release was pH-sensitive, obtaining a targeted
drug release inside the macrophage endosomes. Combining both strategies exhibited a
noteworthy increase in the intracellular antibiotic efficiency in the in vitro latent tuberculo-
sis infection model and excellent antibiotic efficacy in the in vivo antibiotic tests compared
to the free drug solution [100]. SLNs surface modification with mannose residues also
has demonstrated the potential to promote selective uptake by lung tissues, obtaining a
site-specific delivery and reducing side-effects [103].
6.4. Biofilm Formation and Quorum Sensing
Biofilms are structured communities of bacterial cells enclosed in a self-produced
polymeric matrix attached to inert or living surfaces [26]. It has been demonstrated that
biofilm formation presents a physical and biological barrier that reduces drug penetration
and triggers drug resistance. The treatment of biofilm-associated infections is considered a
challenging task, owing to their inherent resistance to (i) antimicrobial agents and (ii) the
host immune system [104]. The use of nanoparticles could overcome some biofilm-related
drug resistance mechanisms mentioned in Section 2.6, such as decreased drug uptake,
increased efflux of the drug or reduced biofilm permeation (Figure 5).
Several works have confirmed the improvement of drug efficiency loading antibiotics
into SLNs to treat infection caused by biofilm-forming bacteria [105–108]. Fazly Bazzaz and
coworkers demonstrated that cationic SLNs formulations were more effective in biomass
reduction of Staphylococcus epidermidis biofilms than the free drug form [106]. However,
from their results, it can be deduced that empty SLNs could also reduce biofilm mass.
Nanomaterials 2021, 11, 1251 15 of 27
Nonetheless, they demonstrated that empty SLNs showed no remarkable reduction of
biofilm-embedded bacterial viability, while rifampin-SLNs significantly reduced biofilm-
forming bacterial viability, improving free drug efficiency [106]. In addition, encapsulation
of clarithromycin in SLNs has demonstrated important improvements in drug character-
istics. Clarithromycin-containing SLNs present enhanced in vitro antibacterial activity in
S. aureus, higher potential in biofilm eradication than free drugs, and an almost 5-fold
improvement in relative oral bioavailability in rats [107].
Interestingly, it has been demonstrated that although some SLNs formulations do not
improve drug efficacy against planktonic bacteria, they can be very useful to increase the
antibacterial activity of the same drug in the same biofilm-forming bacterial strain [109,110].
This is another example of how difficult the extrapolation of an in vitro characteristic to its
in vivo effect can be.
Bacteria use a cell-to-cell communication system known as “quorum sensing” (QS) to
coordinate group behavior, such as the production of virulence factors or biofilm forming
in response to adverse environmental conditions [111]. In this context, eradication of this
communication can be very helpful to reduce virulence factors. In an innovative approach,
Nafee and coworkers incorporated a QS inhibitor that inhibits pyocyanin formation because
pyocyanin concentration has been related to the virulence level of Pseudomonas aeruginosa
infection in cystic fibrosis. They incorporated the inhibitor into different SLNs formulations
(optimized to penetrate the mucus barrier of the lung), and after characterizing them,
they notably observed that inhibitor-loaded SLNs presented an improved anti-virulence
activity compared to the free compound. Surprisingly, they also observed that empty SLNs
presented anti-virulence activity without affecting bacterial viability, and they discovered
that this activity was related to the emulsifiers they had applied (Tween-80 and Poloxamer
407) [112]. This fact is concordant with the results obtained by Fazly Bazzaz and coworkers,
where they observed that empty SLNs composed of Poloxamer 188 and Tween-80 presented
the capability to reduce biofilm mass [106]. Although this effect was no further analyzed by
the authors, as they applied the same surfactants and observed similar anti-biofilm activity,
it can be thought that surfactants may have a bioactive function in biofilm formation also
in this biofilm system. These findings highlight the relevance of SLNs components and
that the pharmacological activity of excipients should not be underestimated.
The main characteristics of different SLNs formulations developed to reduce antibiotic
resistance mechanisms are summarized in Table 1.
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Table 1. Characteristics of SLNs formulations applied to reduce resistance mechanisms.






ps Fluconazole 84.8 ± 4.2 0.291 ± 0.012 −25 ± 4.1 89.6 ± 3.97 Avoidance of drug recognition by efflux pump proteins Candida glabrata [91]



















Rifampicin 440 ± 40 0.37 ± 0.01 − 49.73 ± 0.50 52.45
Relevant and significant increase in drug content within the
macrophage;




























Slower elimination of enrofloxacin after removing extracellular drug;
Stronger inhibition effect against intracellular Salmonella CVCC541
Intracellular Salmonella
CVCC541 [56]
Doxycycline 299 ± 34 0.29 ± 0.027 −28.7 ± 3.2 94.9 ± 3.2 Reduced number of bacteria inside J444A.1 macrophages Intracellular Brucella melitensis [99]
isoniazid 236 ± 9 0.240 ± 0.012 − 19 ± 2 75.13 ± 0.97
Increased intracellular antibiotic efficiency for the in vitro latent
tuberculosis infection model;






















Slower elimination of enrofloxacin after removing extracellular drug;













Mannosylation enhances macrophage uptake
Mannosylation promotes;
selective uptake by lung tissues
J774 macrophages;


















Cefuroxime axetil 279.2 ± 28.5 0.107 ± 0.07 −23.58 70.62 ± 0.82 Drug minimum biofilm inhibitory concentration is 50% lower in SLNs Staphylococcus aureus(ATCC-25923 [105]
Rifampin 101.7 ± 4.7 0.284 ± 0.024 +17.1 ± 0.7 69% ± 2.1 Significant reduction of the viability of bacteria embedded in biofilms Biofilm-producingStaphylococcus epidermidis [106]
Clarithromycin 307 ± 23 0.21 ± 0.04 −29.0 84 ± 9
Enhanced in vitro antibacterial activity;
Higher potential in biofilm eradication compared to free drugs;
Almost 5-fold improvement in relative oral bioavailability
Staphylococcus aureus;
(MTCC86)Wistar rats [107]
Curcumin 423.7 ± 23.2 0.310 ± 0.076 −25.9 ± 6.7 85 Satisfactory inhibition of biofilms Staphylococcus aureus;(ATCC-12600) [108]
Colistin sulfate 300–427 0.3–0.4 n.d. 80–95 Efficient eradication of biofilms Pseudomonas aeruginosa [109]





<100 nm <0.2 −(15–35) Reduction inpyocyanin 73.4
(virulence factor) formation;
High deposition in the bronchial area, the target site
Pseudomonas aeruginosa;
Calu-3 cells [112]
n.d.: not defined in the paper.
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7. Nanoparticles for Drug Combination Strategy
In complex infections, such as in multi and pan-resistant bacterial infections, combin-
ing different drugs is the only alternative that can produce any promising result. Combining
more than one antibiotic can lead to an additive or synergistic effect that reduces the capac-
ity of bacteria to endure drug activity. Nonetheless, this strategy has some drawbacks and
difficulties. Each drug usually presents different pharmacodynamic and pharmacokinetic
properties, and sometimes it is difficult to obtain the same spatial-temporal biodistribution
for both drugs [113].
To achieve this, nanoparticles are very useful for combined therapy because incor-
porating different drugs in the same nanoparticle ensures the presence of both molecules
simultaneously in the same place. Different works have been published demonstrating
the ability of SLNs to perform an efficient drug combination [114–117]. In this context, a
combination of two different antibiotics can increase the success of treatment. For instance,
combining tilmicosin and florfenicol in anionic SLNs enhanced their therapeutic efficacy in
different in vitro studies with bacterial strains and this improvement was also observed in
in vivo experiments done in rats [118] and pigs infection models [2].
Antibiotics can also be combined with molecules of different nature. For example,
clotrimazole and alpha-lipoic acid-loaded cationic SLNs have been obtained to efficiently
treat topical infections of C. albicans [119]. Ampicillin has also been combined with cur-
cumin, a phytochemical derived from the rhizome of Curcuma longa that has antibacterial
and antibiofilm activity. Curcumin was found to restore bacterial susceptibility to an-
tibiotics by inhibiting its biofilm growth mode and rendering it sensitive to antibiotics
in vitro [120]. Combining ampicillin and curcumin in SLNs increased antibiotic effect in
different bacterial strains (i.e., Bacillus subtilis and Corynebacterium diphtheriae) and in some
other cases (i.e., B. subtilis and methicillin-resistant S. aureus), antibiotic resistance was
broken [121]. Rodenak-Kladniew and coworkers demonstrated that hybrid formulations
mixing lipids and chitosan (as cationic biopolymer) to obtain ofloxacin and eugenol co-
loaded SLNs could improve ofloxacin efficiency as well as sustained and localized drug
release, both in vitro and in vivo [122]. Antibiotics can also be combined with bioactive
lipids against biofilm formation [123], with antibacterial peptides obtaining synergistic or
additive effects [124], loaded into SLNs with silver complexed lipids to obtain an enhanced
effect [125], or combined with lipids conjugated to selenium [126]. Antibiotics can also
be combined with other molecules presenting interesting biological activities, i.e., wound
healing factors [127].
Enzymes can also be used for drug combination strategies. For instance, DNase
can be applied to reduce biofilm formation and increase the antimicrobial activity of the
formulation [128,129]. For example, anionic lipid nanoparticles combining DNase and
levofloxacin showed strong antibacterial activity against Gram-positive (S. aureus) and
Gram-negative (P. aeruginosa) bacteria [128].
The main characteristics of applied SLNs formulations for combined therapy are
summarized in Table 2.
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Table 2. Characteristics of SLNs formulations for combined therapy.
Drug Size pdi Zeta-Potential(mV) EE (%) Efficiency Enhancement Organism Ref.
Ampicillin and;
curcumin 163 nm <0.5 n.d. n.d.
Overcome resistance to free antibiotic;
Overcome resistance to free antibiotic;
Minimum bactericidal concentration
decreased 4 times comparing to free drugs;








ofloxacin/eugenol 210.1 ± 5.9 0.418 ± 0.033 15.47 ± 0.21 Ofloxacin 33.5 ± 1.9
Minimum inhibitory concentration six-fold
lower concerning the free antibiotic;




cis-2-decenoic acid 127.2 ± 2.8 0.263 ± 0.017 19.0 ± 7.64
Rifampin 69± 5.10C2DA
46± 4.23
In vitro anti-biofilm activities at both
formation and eradication stages
Staphylococcus aureus;
Staphylococcus epidermidis [123]
Ampicillin + nisin Z 175.457± 17.885 0.279 ± 0.057 −42.078 ± 0.903 Ampicillin 43.826 ± 4.596
Selective toxicity toward bacterial cells;












Ciprofloxacin–selenium 153.6 ±1.8 0.134 ± 0.03 −1.74 ± 0.27 CPF 40.4±4.4 Greater antibacterial activity;Prevented the liver tissue damage
Pseudomonas aeruginosa;
Mice [126]





LL37:84.8 ± 2.7 A1:87 ± 3.5;
LL37:81.6 ± 3.2A1:83.3 ± 4.1
Synergistically enhance the antibacterial
activity;





Levofloxacin + DNase 162.9 ± 5.3 0.340 ± 0.014 −10.3 ± 0.3 Levo 55.9 ± 1.6%
A strong antibacterial activity (less than free
drug);





chitosan + DNAse 212.8 ± 4.21 0.285 ± 0.04 +13.5 ± 1.92 Ana 73.8 ± 1.23% Higher biofilm eradication activity Staphylococcus aureus [129]
n.d.: not defined in the paper.
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8. Solid Lipid Nanoparticles for the Delivery of New Antibiotic Agents
In general, nanoparticles are useful tools to improve drug characteristics and enhance
the efficiency of well-known antibiotics. Nonetheless, nanoparticle potential goes beyond
the mentioned possibilities as they can be applied to deliver molecules that present in-
teresting and promising biological effects but do not exhibit good characteristics of those
attributed to pharmaceuticals. For instance, they do not obey Lipinski’s rules and are
still under development. Here we describe the incorporation in SLNs of oligonucleotides
and conjugation inhibitors because they represent good examples of alternative strategies
against AMR.
8.1. Oligonucleotides
The application of oligonucleotides to modulate the expression of proteins related to
virulence and drug resistance mechanisms on microbes has attracted increasing attention
in the last decades. Unfortunately, oligonucleotide administration has some drawbacks
related to their low stability and difficulties in delivering into bacteria. Oligonucleotides
are easily degraded by exo- and endonucleases present in many biological tissues, fluids,
or biofilms. Therefore, their protection and stabilization are essential to achieve their
therapeutic effect. Moreover, bacterial cell wall architecture, biofilms or access to intracel-
lular pathogens hinder the efficient delivery of oligonucleotides to target sites where the
oligonucleotides exert their regulatory function [130].
In this regard, developing proper DDSs for oligonucleotides administration is an
innovative research field to improve the stability, selective delivery of antisense oligonu-
cleotides [130], or combined delivery for oligonucleotides and ribonucleoproteins, as in the
case of CRISPR/Cas technology [131].
Different groups have demonstrated the ability of SLNs to efficiently deliver oligonu-
cleotides for several applications. For instance, cationic SLNs have been applied for the
co-delivery of an antitumoral drug and mi-RNA to glioblastoma cells obtaining a significant
increase in cell uptake [132]. In another interesting approach, cationic SLNs were loaded
with decoy oligodeoxynucleotides to block STAT3 in ovarian cancer cells obtaining a potent
induction of cell death and cell invasion inhibition [133]. Antisense oligonucleotides have
also been loaded into SLNs to reduce the intracellular activity of SMAD3, obtaining a
significant anti-inflammatory effect [134].
Unfortunately, to our knowledge, only one work has been published about the delivery
of oligonucleotides for antibiotic purposes. In a previously mentioned interesting work,
SLNs were formulated to deliver oligonucleotides to modulate transcription factor decoy
(TFD) expression in two different bacteria: SigH, which specifically blocks the key sigma
factor of the transition phase in Clostridium difficile, and the ferric uptake regulator (Fur),
which controls the import of the essential micronutrient iron into Escherichia coli under
limiting conditions [50]. Three different cationic SLNs formulations were developed
and characterized to achieve optimal oligonucleotide delivery. They demonstrated that
oligonucleotide-loaded SLNs could deliver TFD to cells with high efficiency and to obtain
a specific antibacterial activity, showing a good safety profile in eukaryotic cells at the
concentrations needed for antibacterial activity.
Recently, CRISPR/Cas technology has attracted the attention of many scientists for
the possible application of this technology in the treatment of many complex diseases. This
gene-editing technology has the potential to very selectively insert, delete, or mutate genes
in almost any species, including bacteria. Several researchers have applied this technology
as a selective antibacterial weapon obtaining promising results against resistant bacterial
strains [135–137]. Nonetheless, applying this technology to reduce antibiotic resistance
mechanisms is still in progress, as many details must be considered. For instance, it requires
advances in delivery and targeting specific pathogenic bacteria within complex bacterial
populations, such as our gut microbiome, delivering antibacterials to pathogenic bacteria,
or bacteria-infected host cells [138]. Therefore, selective delivery of the CRISPR/Cas system
can be as important as its own editing activity. Delivery of the CRISPR/Cas system can
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be performed in viral or non-viral vectors. Since viral vectors, although effective, must be
subject to many biosafety considerations, non-viral vectors may represent a very promising
alternative in this field. In this regard, lipid nanoparticles have the potential to efficiently
deliver CRISPR/Cas system into the target cells [131,139]. Thus, applying CRISPR/Cas
technology is a new promising strategy to fight against AMR, provided proper DDSs are
developed, and in this regard, SLNs could be an interesting alternative to viral vectors.
Nonetheless, this possibility is undeveloped and requires further research.
8.2. Conjugation Inhibitors
Bacteria can share genetic material via HGT, disseminating resistance genes and
facilitating the appearance of MDR bacterial strains. Thus, inhibition of this process
could help to decelerate developing the global health crisis, reducing the spreading of
antibiotic resistance genes among bacteria. As mentioned before, conjugation is one of
the main mechanisms by which bacteria can acquire genetic material, and that is why
inhibiting conjugation can be an interesting weapon against drug resistance. Neverthe-
less, these inhibitors should not target essential bacterial functions to avoid developing
new resistance mechanisms. Different conjugation inhibitors have been developed to
attack specific components of the conjugation machinery, such as VirB8-like proteins and
VirB11-like proteins (one of the ATPases of the T4SS) [12], relaxase inhibitors or pilus
blockers [140]. A combination of these inhibitors with antibiotics can be a potent weapon
against antimicrobial-resistant bacteria [140]. In this context, applying SLNs for combined
drug delivery seems an interesting strategy (Figure 6).
Figure 6. Schematic representation of (A) antibiotic resistance spreading by bacterial conjugation. At the beginning of the
process, the bacterium at the left is resistant to antibiotics, but the right is not. After conjugation, both bacteria are resistant
because they have shared the resistance genes coded in the plasmid (circular DNA). (B) Antibiotic resistance spreading
inhibition (continuous line) and antibiotic resistance spreading inhibition in combination with antibiotic treatment (dashed
line). Administration of conjugation inhibitors loaded into SLNs can prevent the conjugation process, avoiding resistant
gene spreading. Additionally, the administration of conjugation inhibitors and antibiotics in the same SLNs treatment of the
infection and inhibition of antibiotic resistance spread could be achieved.
Of particular interest would be applying SLNs to incorporate unsaturated fatty acids
that have been reported as interesting conjugation-inhibitors of VirB11-like protein of R388
plasmid, TrwDR388 [141–143]. Oleic acid, linoleic acid, dehydrocrepenynic acid, tanzawaic
acid or some synthetic 2-alkynoic fatty acid derivatives present potential conjugation
inhibition activities, but their structure and reduced solubility impair their administration as
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drugs. Considering the physicochemical characteristics of these bioactive lipids, incorporation
of these unsaturated fatty acids into SLNs would solve the solubility and administration
problems. Furthermore, SLNs composed of these bioactive lipids can be combined with other
antibiotic drugs to attain potent treatment against antimicrobial infections.
9. Conclusions and Future Perspectives
Antimicrobial resistance is currently one of the biggest threats to global health, and
we urgently need new strategies to tackle it. Considering the drawbacks that developing
new antibacterial drugs represents, the improvement of the efficiency of well-known drugs
by nanocarriers seems the most promising approach.
In this context, solid lipid nanoparticles offer highly interesting opportunities to in-
crease antibiotic efficiency and reverse or reduce antibiotic resistance. SLNs can improve
drug stability, solubility and permeability, enhancing its bioavailability and, most impor-
tantly, drug concentration in the target site. Moreover, they have demonstrated their ability
to overcome some of the basic resistance mechanisms developed by resistant bacterial
strains, such as reduced drug permeation, intracellular infections or biofilm formation.
Additionally, some other mechanistic advantages, such as protection against enzymatic
drug degradation or inhibition of efflux pumps, should be further studied.
Apart from the above-mentioned advantages, SLNs provide an encouraging approach for
a drug combination strategy, facilitating the spatial-temporal distribution of all administrated
molecules. The combination strategy limits bacterial resistance as the additive or synergistic
effect of more than one active molecule reverses the resilience of the resistant strains.
Finally, applying SLNs can open the spectrum of possible bioactive molecules that do
not present good stability, solubility or permeability and that, without their incorporation
into a DDSs, could not be used as antibacterial molecules. Thus, SLNs application broadens
the spectrum of new possible antibiotic agents.
Despite being described for the first time more than twenty years ago and having all
their advantages demonstrated, there are still many questions to answer about applying
SLNs as DDSs. The relation between SLNs characteristics and their biological behavior
regarding bacterial infections is still unclear, possibly because few works have been per-
formed to study the specific interactions between SLNs and bacteria. One reason to explain
this lack of information could be that sometimes it is difficult to observe intracellular drug
fate or interactions between SLNs and bacterial cell walls. Moreover, many studies are cen-
tered on the final efficiency of the therapy, but very few works look beneath it to elucidate
cellular mechanisms implicated in those processes. These unanswered questions difficult
the translation of basic research into clinical trials, which could be why there are still few
trials with SLNs applications. Nonetheless, the urgency of new antimicrobial treatments
deserves a global effort to solve these questions and to improve SLNs’ characteristics
against antibiotic resistance dissemination.
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